152 related articles for article (PubMed ID: 25721042)
1. Malignant TOXication of T cells.
Odum N
Blood; 2015 Feb; 125(9):1361-2. PubMed ID: 25721042
[TBL] [Abstract][Full Text] [Related]
2. Evidence of an oncogenic role of aberrant TOX activation in cutaneous T-cell lymphoma.
Huang Y; Su MW; Jiang X; Zhou Y
Blood; 2015 Feb; 125(9):1435-43. PubMed ID: 25548321
[TBL] [Abstract][Full Text] [Related]
3. Molecular profiling of TOX-deficient neoplastic cells in cutaneous T cell lymphoma.
Xu J; Huang H; Wang S; Chen Y; Yin X; Zhang X; Zhang Y
Arch Dermatol Res; 2020 Sep; 312(7):513-525. PubMed ID: 31676945
[TBL] [Abstract][Full Text] [Related]
4. TOX expression in different subtypes of cutaneous lymphoma.
Morimura S; Sugaya M; Suga H; Miyagaki T; Ohmatsu H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
Arch Dermatol Res; 2014 Nov; 306(9):843-9. PubMed ID: 25216799
[TBL] [Abstract][Full Text] [Related]
5. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
[TBL] [Abstract][Full Text] [Related]
6. Localization of clonal T cells to the epidermis in cutaneous T-cell lymphoma.
Fivenson DP; Hanson CA; Nickoloff BJ
J Am Acad Dermatol; 1994 Nov; 31(5 Pt 1):717-23. PubMed ID: 7929915
[TBL] [Abstract][Full Text] [Related]
7. Low FAS/CD95 expression by CTCL correlates with reduced sensitivity to apoptosis that can be restored by FAS upregulation.
Wu J; Nihal M; Siddiqui J; Vonderheid EC; Wood GS
J Invest Dermatol; 2009 May; 129(5):1165-73. PubMed ID: 18923451
[TBL] [Abstract][Full Text] [Related]
8. The emergence of Sézary cells during the treatment of cutaneous T-cell lymphoma.
Sato M; Ishikawa O; Miyachi Y
Br J Dermatol; 1995 Nov; 133(5):810-3. PubMed ID: 8555042
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-13 is overexpressed in cutaneous T-cell lymphoma cells and regulates their proliferation.
Geskin LJ; Viragova S; Stolz DB; Fuschiotti P
Blood; 2015 Apr; 125(18):2798-805. PubMed ID: 25628470
[TBL] [Abstract][Full Text] [Related]
10. Paucity of FOXP3+ cells in skin and peripheral blood distinguishes Sézary syndrome from other cutaneous T-cell lymphomas.
Klemke CD; Fritzsching B; Franz B; Kleinmann EV; Oberle N; Poenitz N; Sykora J; Banham AH; Roncador G; Kuhn A; Goerdt S; Krammer PH; Suri-Payer E
Leukemia; 2006 Jun; 20(6):1123-9. PubMed ID: 16557241
[TBL] [Abstract][Full Text] [Related]
11. The mutational landscape of cutaneous T cell lymphoma and Sézary syndrome.
da Silva Almeida AC; Abate F; Khiabanian H; Martinez-Escala E; Guitart J; Tensen CP; Vermeer MH; Rabadan R; Ferrando A; Palomero T
Nat Genet; 2015 Dec; 47(12):1465-70. PubMed ID: 26551667
[TBL] [Abstract][Full Text] [Related]
12. Expression of intercellular adhesion molecule 3 (CDw50) on endothelial cells in cutaneous lymphomas. A comparative study between nodal and cutaneous lymphomas.
Dommann SN; Dommann-Scherrer CC; Ziegler T; Meyer J; Trüeb RM; Kündig T; Panizzon R; Burg G
Am J Dermatopathol; 1997 Aug; 19(4):391-5. PubMed ID: 9261475
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of c-myb in leukaemic and non-leukaemic variants of cutaneous T-cell lymphoma.
Poenitz N; Simon-Ackermann J; Gratchev A; Qadoumi M; Klemke CD; Stadler R; Kremer A; Radenhausen M; Henke U; Assaf C; Utikal J; Goerdt S; Dippel E
Dermatology; 2005; 211(2):84-92. PubMed ID: 16088151
[TBL] [Abstract][Full Text] [Related]
14. Cutaneous T-cell lymphoma. Refinement in the application of controversial histologic criteria.
Glusac EJ; Shapiro PE; McNiff JM
Dermatol Clin; 1999 Jul; 17(3):601-14, ix. PubMed ID: 10410861
[TBL] [Abstract][Full Text] [Related]
15. Transformation of Sézary syndrome and the sign of Leser-Trélat: a histopathologic study.
Wieselthier JS; Bhawan J; Koh HK
J Am Acad Dermatol; 1990 Sep; 23(3 Pt 1):520-2. PubMed ID: 2145329
[No Abstract] [Full Text] [Related]
16. Avicin D selectively induces apoptosis and downregulates p-STAT-3, bcl-2, and survivin in cutaneous T-cell lymphoma cells.
Zhang C; Li B; Gaikwad AS; Haridas V; Xu Z; Gutterman JU; Duvic M
J Invest Dermatol; 2008 Nov; 128(11):2728-2735. PubMed ID: 18496567
[TBL] [Abstract][Full Text] [Related]
17. TOX expression in cutaneous T-cell lymphomas: an adjunctive diagnostic marker that is not tumour specific and not restricted to the CD4(+) CD8(-) phenotype.
Schrader AM; Jansen PM; Willemze R
Br J Dermatol; 2016 Aug; 175(2):382-6. PubMed ID: 26931394
[TBL] [Abstract][Full Text] [Related]
18. Tumor microenvironment in mycosis fungoides and Sézary syndrome.
Rubio Gonzalez B; Zain J; Rosen ST; Querfeld C
Curr Opin Oncol; 2016 Jan; 28(1):88-96. PubMed ID: 26632770
[TBL] [Abstract][Full Text] [Related]
19. Memorials and mandates for cutaneous lymphomas.
Heald PW
Arch Dermatol; 2003 Jul; 139(7):926-8. PubMed ID: 12873891
[No Abstract] [Full Text] [Related]
20. Folliculotropic Sézary syndrome: a new variant of cutaneous T-cell lymphoma.
Gerami P; Guitart J
Br J Dermatol; 2007 Apr; 156(4):781-3. PubMed ID: 17286634
[No Abstract] [Full Text] [Related]
[Next] [New Search]
